Skip to main content
NCD 210.2.1 · version 1

NCD 210.2.1: Screening for Cervical Cancer with Human Papillomavirus (HPV)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 210.2.1

Benefit category
Additional Preventive Services
Effective date
07/09/2015
Implemented 03/07/2016
Transmittal
Transmittal 189
Versions published
1
Manual section
210
Prevention, NCD Manual (Pub. 100-03) chapter 1 part 4

TL;DR

NCD 210.2.1 sets Medicare's national policy for screening for cervical cancer with human papillomavirus (hpv) under the benefit category "Additional Preventive Services", effective 07/09/2015 and implemented 03/07/2016. Effective for services performed on or after July 9, 2015, CMS has determined that the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Medicare covers a screening pelvic examination and Pap test for all female beneficiaries at 12 or 24 month intervals, based on specific risk factors. See 42 C.F.R. § 410.56; Medicare National Coverage Determinations Manual, § 210.2.1 Current Medicare coverage does not include the HPV testing. Pursuant to §1861(ddd) of the Social Security Act, the Secretary may add coverage of "additional preventive services" if certain statutory requirements are met.

Indications and limitations of coverage

B. Nationally Covered Indications

Effective for services performed on or after July 9, 2015, CMS has determined that the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries aged 30 to 65 years in conjunction with the Pap smear test. CMS will cover screening for cervical cancer with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations.

C. Nationally Non-Covered Indications

Unless specifically covered in this NCD, any other NCD, by statute or regulation, preventive services are non-covered by Medicare.

D. Other

N/A

(This NCD last reviewed July 2015.)

Text reproduced from the CMS Medicare Coverage Database record for NCD 210.2.1 version 1. View the original on cms.gov.

Local policies that build on this NCD

4 active Local Coverage Determinations cite NCD 210.2.1 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing, LCD L39044 · Wisconsin Physicians Service Insurance Corporation
  • L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Palmetto GBA
  • L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Noridian Healthcare Solutions, LLC
  • L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · CGS Administrators, LLC

How MACs bill NCD 210.2.1

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 4 current articles in the Medicare Coverage Database name NCD 210.2.1, 4 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A58710: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58720: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58747: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-05-14 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

852 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58761: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39044 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 210.2.1, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00442N Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing (New, Closed)

Revision history

02/2016 - The purpose of this this Change Request (CR) is that CMS has determined that for dates of service on or after effective July 9, 2015, evidence is sufficient to add HPV testing under specified conditions. Effective date: 07/09/2015 Implementation date: 03/07/2016 ( TN 189 ) (CR9434)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 210.2.1

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 210.2.1

What does NCD 210.2.1 cover?

Effective for services performed on or after July 9, 2015, CMS has determined that the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries aged 30 to 65 years in conjunction with the Pap smear test. CMS will cover screening for cervical cancer with the appropriate U.S. Food… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 210.2.1 take effect?

The current version (1) is effective 07/09/2015, implemented 03/07/2016, published in transmittal 189. This is the only published version.

Does a Local Coverage Determination override NCD 210.2.1?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

CMS guidance

The Medicare Learning Network publication that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.